Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Sibutramine lost and found.

O Bosello1, M O Carruba, E Ferrannini

  • 1Department of Biomedical and Surgical Sciences, University of Verona, Italy. ottavio.bosello@univr.it

Eating and Weight Disorders : EWD
|November 28, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Body mass index (BMI), waist circumference (WC), waist-to-height ratio (WHtR) e waist body mass index (wBMI): Which is better?

Endocrine·2022
Same author

Predictors of type 2 diabetes relapse after Roux-en-Y Gastric Bypass: A ten-year follow-up study.

Diabetes & metabolism·2021
Same author

Mannose is an insulin-regulated metabolite reflecting whole-body insulin sensitivity in man.

Metabolism: clinical and experimental·2019
Same author

Impaired beta cell sensitivity to incretins in type 2 diabetes is insufficiently compensated by higher incretin response.

Nutrition, metabolism, and cardiovascular diseases : NMCD·2017
Same author

Back to glycemic control: An alternative look at the results of cardiovascular outcome trials in type 2 diabetes.

Nutrition, metabolism, and cardiovascular diseases : NMCD·2017
Same author

Obesity and carotid artery remodeling.

Nutrition & diabetes·2015

Obesity is a growing global health crisis. Sibutramine, a weight-loss medication, shows a favorable risk/benefit profile for managing obesity when used correctly, despite past market withdrawals.

Area of Science:

  • Medical Science
  • Public Health
  • Pharmacology

Background:

  • Obesity is a chronic disease and global epidemic, increasing health risks and costs.
  • Italian obesity rates were 9% (obesity) and 33% (overweight) in 2000, rising significantly.
  • Weight loss improves obesity-related health issues.

Purpose of the Study:

  • To evaluate the efficacy and safety of sibutramine for obesity management.
  • To address the temporary withdrawal of sibutramine from the Italian market.
  • To assess the overall risk/benefit profile of sibutramine in pathological obesity treatment.

Main Methods:

  • Review of worldwide efficacy and safety data for sibutramine.
  • Analysis of adverse event reports and mortality rates.

Related Experiment Videos

  • Comparison of sibutramine-related fatal reports with obese women's mortality rates.

    • Main Results:

    • Sibutramine, a serotonin and noradrenaline reuptake inhibitor, was approved for obesity treatment in 1997.
    • Adverse event reports led to a temporary withdrawal in Italy in 2002.
    • Worldwide data review indicates a favorable overall risk/benefit profile for sibutramine.

    Conclusions:

    • The risk/benefit profile of sibutramine remains favorable for obesity management.
    • Fatal reports involving sibutramine are significantly lower than obese women's mortality rates.
    • Correct use of sibutramine is supported by strong evidence for obesity management.